RecallDepth
Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-750-33.

This recall is currently active, issued July 16, 2025. It was issued by Breckenridge Pharmaceutical, Inc..

Company
Breckenridge Pharmaceutical, Inc.
Recall Initiated
June 30, 2025
Posted
July 16, 2025
Recall Number
D-0511-2025
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
12,242 30-count bottles
Firm Location
Berkeley Heights, NJ, United States
Official Source
View on FDA website ↗

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Distribution

U.S. Nationwide

Lot / Code Info

Lot # 230199, Exp. Date 01/31/2026

More recalls by Breckenridge Pharmaceutical, Inc.

View all recalls by this company →

Other recent Class II Drug recalls